Sugi Predict

Sugi Predict / Compounds / SCHEMBL717299

SCHEMBL717299

SCHEMBL717299

CCOC(=O)C(=O)C(CC)C(=O)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.39
▸ GLO1 Q04760 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ GAA P10253 2/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ MGAM O43451 1/20 0.37
▸ SI P14410 1/20 0.37
▸ MGAM2 Q2M2H8 1/20 0.37
▸ SOAT1 P35610 1/20 0.37
▸ EGLN1 Q9GZT9 1/20 0.36
▸ TDP1 Q9NUW8 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MAPT P10636 1/20 0.35
▸ MMP8 P22894 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7518295 0.87 GAA (0.39) ALDH1A1NPSR1GLO1LMNAHSD17B10
SCHEMBL9591544 0.86 EGLN1 (0.41) ALDH1A1NPSR1GLO1LMNAHSD17B10
SCHEMBL28278066 0.85 ALDH1A1 (0.36) ALDH1A1NPSR1GLO1LMNAHSD17B10
SCHEMBL10414972 0.85 ALDH1A1 (0.36) ALDH1A1NPSR1GLO1LMNAHSD17B10
SCHEMBL10932012 0.84 SOAT1 (0.52) ALDH1A1NPSR1GLO1LMNAHSD17B10
SCHEMBL230068 0.83 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL4773196 0.83 TDP1 (0.38) ALDH1A1NPSR1GLO1LMNAHSD17B10
SCHEMBL3061368 0.82 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL25181738 0.81 MGAM (0.43) ALDH1A1NPSR1GLO1LMNAHSD17B10
SCHEMBL5146402 0.81 TDP1 (0.37) ALDH1A1NPSR1GLO1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12054480-B2 Compounds for treating cannabinoid toxicity and acute cannabinoid overdose MAKSCIENTIFIC, LLC (US) 2024-08-06 — — US disclosed
US-20220033393-A1 Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose MAKSCIENTIFIC, LLC 2022-02-03 — — US disclosed
CN-105980386-B Pyrazolo compounds and uses thereof 基因泰克公司 2021-08-13 — — CN disclosed
EP-2970307-B1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2020-03-11 — — EP disclosed
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-03-07 — — US disclosed
EP-2816040-B1 Process for the production of CCR2 receptor antagonists and intermediates thereof CENTREXION THERAPEUTICS CORP (US) 2018-10-17 — — EP disclosed
EP-3371151-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS Agency For Science, Technology And Research (SG) 2018-09-12 — — EP disclosed
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 — — US disclosed
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 — — US disclosed
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 — — US disclosed
US-8048898-B2 Inhibitor of binding of S1P1 TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-11-01 — — US disclosed
EP-2379525-A1 CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD Boehringer Ingelheim International GmbH (DE) 2011-10-26 — — EP disclosed
WO-2011080568-A2 NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-07-07 — — WO disclosed
US-20100234594-A1 INHIBITOR OF BINDING OF S1P1 TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-09-16 — — US disclosed
WO-2010070032-A1 CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 — — WO disclosed
EP-2177512-A1 INHIBITOR OF BINDING OF S1P1 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 — — EP disclosed
EP-0863882-B1 AMINO SUBSTITUTED PYRIMIDINES AND TRIAZINES JANSSEN PHARMACEUTICA NV (BE) 2002-02-06 — — EP disclosed
US-6288060-B1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS; ANXIOLYTIC, ANTIDEPRESSANT, ANTIINFLAMMATORY AGENTS; EATING DISORDERS NEUROCRINE BIOSCIENCES, INC. 2001-09-11 — — US disclosed
EP-0863882-A1 AMINO SUBSTITUTED PYRIMIDINES AND TRIAZINES JANSSEN PHARMACEUTICA N.V. (BE) 1998-09-16 — — EP disclosed
WO-1997014684-A1 AMINO SUBSTITUTED PYRIMIDINES AND TRIAZINES JANSSEN PHARMACEUTICA N.V. (BE) 1997-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS SMYD3, SMYD2, EHMT1 ALDH1A1 373/4885NPSR1 4662/4885GLO1 1409/4885
US-10035801-B2 Pyrazolo compounds and uses thereof KDM5A, KDM5C, KDM5B ALDH1A1 1424/4885NPSR1 4604/4885GLO1 806/4885
US-20220033393-A1 Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose CNR1, CNR2, OPRM1 ALDH1A1 2782/4885NPSR1 111/4885GLO1 4713/4885
US-20100234594-A1 INHIBITOR OF BINDING OF S1P1 S1PR1, S1PR3, EDNRB ALDH1A1 1199/4885NPSR1 217/4885GLO1 3563/4885
US-12054480-B2 Compounds for treating cannabinoid toxicity and acute cannabinoid overdose CNR1, CNR2, OPRM1 ALDH1A1 2782/4885NPSR1 111/4885GLO1 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.